Skip to content
OmniAb
  • About
    • Overview
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antigen Design
    • Antibody Generation
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmniTaur
      • Bispecific Platforms
    • Screening
      • GEM
      • xPloration
    • Antibody Optimization
    • Ion Channel and Transporter Technology
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact
OmniAb
  • About
    • Overview
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antigen Design
    • Antibody Generation
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmniTaur
      • Bispecific Platforms
    • Screening
      • GEM
      • xPloration
    • Antibody Optimization
    • Ion Channel and Transporter Technology
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact

Scientific Publications

Presentations
Opening the Barn Door to Antibody Discovery

Antibody Engineering & Therapeutics Conference, 2022
...
Read More

Presentations
High-Specificity OmniAb Antibodies for Bispecific Applications; 2022 World Bispecific Conference

2022
...
Read More

Presentations
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose...

Cell Reports, 2022
...
Read More

Presentations
Discovery, Expression, and Characterization of Neutralizing Picobodies against SARS-CoV2

Antibody Engineering and Therapeutics, 2021
At 4-6 KD, “picobodies” represent the smallest known Ig-derived binding moiety capable of high affinity interactions with target proteins ...
Read More

Presentations
Chicken Heavy Chain only antibodies to SARS-CoV2

Antibody Engineering and Therapeutics, 2021
Single domain antibodies are found naturally in camelids and sharks, and humanized versions have been engineered ...
Read More

Presentations
Antibody Discovery Powered By OmniAb

Antibody Engineering and Therapeutics, 2021
The OmniAb platform couples cutting edge screening and data mining technologies with highly validated antibody generation systems ...
Read More

Publications
Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for...

MAbs, 2021
Bispecific antibodies are an important and growing segment in antibody therapeutics, particularly in the immuno-oncology space. Manufacturing of a bispecific ...
Read More

Presentations
xPloration®: High Throughput B Cell Profiling for Antibody Discovery from OmniAb Immune Repertoires

2020
The success of a therapeutic antibody is directly related to its biological activity, which is a function of the epitope ...
Read More

Publications
Comparisons of the antibody repertoires of a humanized rodent and humans by high throughput sequencing

2020
The humanization of animal model immune systems by genetic engineering has shown great promise for antibody discovery, tolerance studies and ...
Read More

Publications
Expression of human lambda expands the repertoire of OmniChickens

PLOS ONE, 2020
Most of the approved monoclonal antibodies used in the clinic were initially discovered in mice. However, many targets of therapeutic ...
Read More

Presentations
OmniTaur™: Ultralong CDR3 cow antibodies for challenging targets

2020
Bovine antibodies are unusual in having exceptionally long heavy chain CDR3 regions, with an average length of 25 amino acids, ...
Read More

Presentations
Benchmarking discovery-stage antibodies from OmniChicken (against clinical-stage antibodies from other sources)

2019
Presentation by Bill Harriman and Shelley Izquierdo ...
Read More
  • 1
  • 2
  • 3
  • 4
Loading...

About

  • Overview
  • Team
  • Board of Directors
  • Careers

Partnerships

  • Overview
  • Why Partner with OmniAb?
  • Partner Pipeline
  • Contact Business Development

Technology

  • Overview
  • Antigen Design
  • Antibody Generation
  • Screening
  • Antibody Optimization
  • Ion Channel and Transporter Technology
  • Scientific Publications

OmniAb, Inc.
5980 Horton Street
Suite 600
Emeryville, CA 94608

[email protected]
[email protected]

Contact | Privacy Policy | Disclaimer

© 2023 OmniAb, Inc. All rights reserved.